Malia Potts

Dr. Malia Potts

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2016 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
APAlexander T. Piala
Alexander T. Piala
RARadha Akella
Radha Akella
MPMalia Potts
Malia Potts
SDStephanie A. Dudics-Giagnocavo
Stephanie A. Dudics-Giagnocavo
HHHaixia He
Haixia He
EGElizabeth J. Goldsmith
Elizabeth J. Goldsmith

26 May 2022 in Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
Verified
Journal Article
Closed access
SBswarna beesetti
swarna beesetti
SSShyam Sirasanagandla
Shyam Sirasanagandla
SSSadie Miki Sakurada
Sadie Miki Sakurada
SPShondra M. Pruett-Miller
Shondra M. Pruett-Miller
RSRhea Sumpter
Rhea Sumpter
MPMalia Potts
Malia Potts

15 March 2017 in Marine Drugs
Verified
Journal Article
Open access
PDF file
RVRachel Vaden
Rachel Vaden
NONathaniel W. Oswald
Nathaniel W. Oswald
MPMalia Potts
Malia Potts
JMJohn B MacMillan
John B MacMillan
MWMichael A. White
Michael A. White
Chemicals found in nature have evolved over geological time scales to productively interact with biological molecules, and thus represent an effective resource for pharmaceutical development. Marine-derived bacteria are rich sources of chemically diverse, bioactive secondary metabolites, but harnessing this diversity for biomedical benefit is limited by challenges associated with natural product purification and determination of biochemical mechanism. Using Functional Signature Ontology (FUSION), we report the parallel isolation and characterization of a marine-derived natural product, N6,N6-dimethyladenosine, that robustly inhibits AKT signaling in a variety of non-small cell lung cancer cell lines. Upon validation of the elucidated structure by comparison with a commercially available sample, experiments were initiated to understand the small molecule’s breadth of effect in a biological setting. One such experiment, a reverse phase protein array (RPPA) analysis of >50 kinases, indicated a specific cellular response to treatment. In all, leveraging the FUSION platform allowed for the rapid generation and validation of a biological mechanism of action hypothesis for an unknown natural product and permitted accelerated purification of the bioactive component from a chemically complex fraction.

2 June 2021 in PLOS Biology
Verified
Journal Article
Open access
PDF file
JPJung Mi Park
Jung Mi Park
SYSeung Wook Yang
Seung Wook Yang
WZWei Zhuang
Wei Zhuang
ABAsim K. Bera
Asim K. Bera
YLYan Liu
Yan Liu
MPMalia Potts
Malia Potts
Nutrient-responsive protein kinases control the balance between anabolic growth and catabolic processes such as autophagy. Aberrant regulation of these kinases is a major cause of human disease. We report here that the vertebrate nonreceptor tyrosine kinase Src-related kinase lacking C-terminal regulatory tyrosine and N-terminal myristylation sites (SRMS) inhibits autophagy and promotes growth in a nutrient-responsive manner. Under nutrient-replete conditions, SRMS phosphorylates the PHLPP scaffold FK506-binding protein 51 (FKBP51), disrupts the FKBP51-PHLPP complex, and promotes FKBP51 degradation through the ubiquitin-proteasome pathway. This prevents PHLPP-mediated dephosphorylation of AKT, causing sustained AKT activation that promotes growth and inhibits autophagy. SRMS is amplified and overexpressed in human cancers where it drives unrestrained AKT signaling in a kinase-dependent manner. SRMS kinase inhibition activates autophagy, inhibits cancer growth, and can be accomplished using the FDA-approved tyrosine kinase inhibitor ibrutinib. This illuminates SRMS as a targetable vulnerability in human cancers and as a new target for pharmacological induction of autophagy in vertebrates.

20 October 2020 in Cell Death Discovery
Verified
Journal Article
Open access
PDF file
JCJane E. Craig
Jane E. Craig
JMJoseph N. Miller
Joseph N. Miller
RRRaju R. Rayavarapu
Raju R. Rayavarapu
ZHZhenya Hong
Zhenya Hong
GBGamze B. Bulut
Gamze B. Bulut
MPMalia Potts
Malia Potts
Mitochondria are vital organelles that coordinate cellular energy homeostasis and have important roles in cell death. Therefore, the removal of damaged or excessive mitochondria is critical for maintaining proper cellular function. The PINK1-Parkin pathway removes acutely damaged mitochondria through a well-characterized mitophagy pathway, but basal mitochondrial turnover occurs via distinct and less well-understood mechanisms. Here we report that the MEKK3-MEK5-ERK5 kinase cascade is required for mitochondrial degradation in the absence of exogenous damage. We demonstrate that genetic or pharmacological inhibition of the MEKK3-MEK5-ERK5 pathway increases mitochondrial content by reducing lysosome-mediated degradation of mitochondria under basal conditions. We show that the MEKK3-MEK5-ERK5 pathway plays a selective role in basal mitochondrial degradation but is not required for non-selective bulk autophagy, damage-induced mitophagy, or restraint of mitochondrial biogenesis. This illuminates the MEKK3-MEK5-ERK5 pathway as a positive regulator of mitochondrial degradation that acts independently of exogenous mitochondrial stressors.

17 November 2022 in Cell Chemical Biology
Verified
Journal Article
Closed access
MPMalia Potts
Malia Potts